KAI and Sankyo Enter Global Alliance in Cardiovascular Disease
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 68 (Table of Contents)
Published: 6 Feb-2006
DOI: 10.3833/pdr.v2006.i68.556 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
KAI Pharmaceuticals and Sankyo entered into agreement to develop KAI-9803 which is in phase 1/2 clinical trials for treating myocardial tissue death and associated congestive heart failure in acute myocardial infarction...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS